control both leukocyte trafficking and phenotype (7-11). These autacoids also threatening complication of TBM), and by enhancing the resolution of intra-cerebral 96 inflammation through the increased expression of SPMs (14) . The trial found that in 97 patients with microbiologically confirmed TBM, aspirin was associated with reduced 98 brain infarcts and/or death in the first 60 days of treatment.
99
Little is known about the regulation of lipid mediators, and in particular SPM, 100 in the cerebrospinal fluid (CSF) during TBM. Thus, in the present studies we 101 investigated whether CSF lipid mediator concentrations were altered with increasing 102 disease severity. We found that concentrations of a number of SPM families were 103 reduced with increasing disease severity. This was linked with an upregulation of 104 inflammation-initiating eicosanoids, including prostaglandins and cystenyl 105 leukotrienes. Pre-treatment CSF lipid mediator concentrations were also found to be 106 predictive of outcome with distinct lipid mediator profiles obtained in those patients 107 that were alive at the end of the study versus those that died during the study.
108
Finally, we also found that in aspirin-treated patients there was a dose-dependent 
146
In order to gain further insights into the mediator pathways that were 147 differentially regulated between these patient groups we next interrogated the 148 biosynthetic pathways for each of the essential fatty acid metabolomes. This 149 demonstrated that in patients with an MRC score of 2 and 3, when compared with 150 patients with an MRC score of 1, there was a significant reduction in two pro-151 resolving mediator families, the n-3 docosapentaenoic acid-derived resolvins (RvDn-3 152 DPA) and the arachidonic acid-derived lipoxins (LX). This was coupled with a 153 significant increase in the pro-inflammatory arachidonic acid-derived prostaglandins
154
(PG) and leukotrienes (LT; Figure 1D ). Table 2 ). In addition, we also observed increased concentrations 176 of LTE4, the terminal product in the cysteinyl leukotriene biosynthetic metabolome 177 and that was recently found to be also bioactive (19), with increasing disease 178 severity, although the correlation was not statistically significant after correction for 179 multiple testing (Figure 2C, Supplemental 
212
We next conducted lipid mediator biosynthetic pathway analysis to evaluate 
228
(Supplemental Table 5 and Figure 4B ). Out of these mediators 15-epi-LXB4 was
229
found to be significantly reduced after multiple correction. This lipid mediator was 230 also a strong predictor of mortality in TBM as demonstrated by LASSO regression 231 analysis (Supplemental Table 6 ).
233
Aspirin administration upregulates CSF concentrations of select pro-resolving 234 mediators during TBM
235
We recently reported that treatment with aspirin, dexamethasone and anti- 
325
In summary, the present findings uncover novel mechanisms in the 326 pathophysiology of TBM that may have relevance to all forms of tuberculosis.
327
Disease severity is associated with an alteration in lipid mediator expression and a 328 dysregulation in the production of several SPM pathways; a mechanism that is also 329 linked with a poor prognosis. This dysregulation was at least in part restored by 330 aspirin, lending support to the hypothesis that TBM arises from a failure of the host to 331 engage resolution mechanisms and offering novel treatment strategies.
Materials and Methods

333
Clinical study:
334
The patients in the current study were enrolled in a clinical trial of adjunctive aspirin,
335
the design and conduct of which have been previously described (14 369 min, and the flow rate was maintained at 0.5 ml/min. QTrap 6500+ was operated in 370 negative ionization mode using a multiple reaction monitoring method as in (30).
371
In the analysis of peptide-lipid conjugated mediators eluted in the methanol 372 fraction, an Agilent Poroshell 120 EC-C18 column (100 mm x 4.6 mm x 2.7 μm) was 373 kept at 50°C and mediators were eluted using a mobile phase consisting of methanol- 
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